Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the ...

The U.S. Food and Drug Administration (FDA) has upgraded a recall of tomatoes sold in three southern states to a Class I recall, the most serious level, because the tomatoes may be contaminated ...

After decades of research, the U.S. Food and Drug Administration (FDA) has approved a test that can detect the buildup of amyloid plaques in the brain—a key marker of Alzheimer’s disease, ...

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

The US Food and Drug Administration (FDA) has expanded the indications of an imaging agent developed by GE HealthCare, which will likely put it at the forefront of the Alzheimer’s diagnostics arena.

Local News FDA approves first twice-yearly HIV prevention shot Yeztugo showed promising results in clinical trials. One study involving women in Africa reported 100% efficacy, with zero HIV ...

Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510 (k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic ...

Supreme court widens court options for vaping companies pushing back against FDA rules By LINDSAY WHITEHURST The Associated Press,Updated June 20, 2025, 2:39 p.m.

This initiative follows the landmark FDA clearance of the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test developed by Fujirebio Diagnostics in May 2025.

The Food and Drug Administration (FDA) has approved Harliku ™ (nitisinone) for the reduction of urine homogentisic acid (HGA) in adult patients with alkaptonuria. Alkaptonuria (AKU) is a rare ...